Joshua A. Gustafson

Supplementary Table S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Table S2. Representativeness of Study Participants.

Supplementary Table S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Table S1 – Demographics and Baseline Characteristics for All Enrolled Subjects.

Supplementary Table S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Table S3 – Bridging Therapy Received.

Supplementary Figure S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Figure S2. Differential expression by flow cytometry of differentiation (A + B), activation/exhaustion markers (C + D) of paired 2GS and 3GS products for the 6 patients who had both products generated, separated by CD4 (A + C) and CD8 (B …

Supplementary Figure S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Figure S4. Pre- and post-CAR T peripheral blood cytokine profiling comparing cytokines for patients on Arm A and Arm B, showing no statistical differences between groups.

Supplementary Figure S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Figure S3. Kidney biopsy of S16 demonstrating A) no inflammatory infiltrate on H&E sections, B)intact CD171+ renal tubules and C) no CD3+ infiltrate.

Supplementary Table S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Table S4 – Toxicities Possibly, Probably or Definitely Related to First Infusion of CAR T Cells.

Data from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Abstract Purpose: Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 (NCT 02311621) was a first-in-human clinical trial for patients with relapsed and refractory neuroblastoma using chimeric antigen receptor (CAR) T cells targeting L1CAM, an adhesion molecule that is overexpressed …

Supplementary Figure S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

Supplementary Figure S1. A)Gating strategy of peripheral blood CAR T cell detection by flow cytometry. B)Gating strategy for paired 2GS/3GS products evaluating differentiation state and activation/exhaustion state by flow cytometry.

Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial

Rebecca Ronsley, Wenjun Huang, Ethan Rohlf, Kristy Seidel et autres

BACKGROUND: High-grade central nervous system (CNS) tumors carry a poor prognosis with limited curative options if first-line therapy fails. B7-H3 is expressed in many of these tumors, and chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapeutic strategy. METHODS: BrainChild-03 …

us (code pays fourni par la source)

The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma

Navin R. Pinto, Annette Künkele, Catherine Michelle Albert, Mallory R. Taylor et autres

PURPOSE: Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 (NCT02311621) was a first-in-human clinical trial for patients with relapsed and refractory neuroblastoma using chimeric antigen receptor (CAR) T cells targeting L1CAM, an adhesion molecule that is overexpressed in neuroblastoma …

us, de (code pays fourni par la source)

Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma

Andrea Timpanaro, Edward Z. Song, Ryma Toumi, Leonel Elena-Sanchez et autres

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor affecting over 300 children annually in the United States. Chimeric antigen receptor (CAR) T cells are a targeted immune effector cell therapy with substantial clinical benefit against hematologic cancers. Against …

us, au (code pays fourni par la source)